Ultra-Short Acting Insulin Versus Short Acting Insulin Effect on Postprandial Hyperglycemia AKA RCT Comparing Linjeta Versus Humalog in Pumps: Effect on Postprandial Glycemia

The purpose of this study is to determine if the use of Linjeta(tm) insulin when compared to Humalog will result in significantly lower episodes of hyperglycemia and hypoglycemia after a breakfast meal.

Start Date01 Apr 2010

Sponsor / Collaborator

Stanford University

[+2]

NCT01110746 / CompletedPhase 3

A Double-blind Study of the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy

The purpose of this study is to evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin during SC Insulin Pump Therapy.

Start Date01 Feb 2010

Sponsor / Collaborator

Biodel, Inc.

NCT01235039 / CompletedPhase 1/2

A Single Center, Double Blind, Randomized Crossover Study Evaluating the Bioequivalence of VIAject®7 Compared to VIAject®25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus

The primary objective of this study is to test for bioequivalence of VIAject®7 and VIAject®25 and to compare the pharmacokinetic/Pharmacodynamic/tolerability characteristics of VIAject®7 with those of VIAject®25 and insulin lispro.

Start Date01 Jul 2009

Sponsor / Collaborator

Biodel, Inc.

100 Clinical Results associated with Insulin prandial injectable(Albireo Pharma, Inc.)

100 Translational Medicine associated with Insulin prandial injectable(Albireo Pharma, Inc.)

100 Patents (Medical) associated with Insulin prandial injectable(Albireo Pharma, Inc.)

Literatures (Medical) associated with Insulin prandial injectable(Albireo Pharma, Inc.)

17 Feb 2017·Postgraduate MedicineQ4 · MEDICINE

Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes

Q4 · MEDICINE

Review

Author: Aronoff, Stephen L.

While glycemic control is routinely assessed using HbA1c and fasting glucose measures, postprandial glucose (PPG) is also an important contributor of overall glycemia. Furthermore, PPG excursions have been linked to complications of diabetes. This review examines the effects of glucose-lowering therapies (including treatments administered at mealtime) on postprandial hyperglycemia in patients with type 2 diabetes. A PubMed search was conducted to identify clinical studies of treatments for mealtime glucose control in type 2 diabetes. Different treatments may have comparable effects on HbA1c but varying effects on PPG control and glucose fluctuations. Older classes of oral glucose-lowering treatments administered at mealtime to lower PPG include meglitinides and α-glucosidase inhibitors. Injectable therapies, including prandial insulin analogs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and the amylin analog pramlintide, all effectively target postprandial hyperglycemia. Compared with longer-acting GLP-1RAs, short-acting GLP-1RAs, such as exenatide twice daily and lixisenatide once daily, have a greater effect on PPG control, which is primarily mediated by a more pronounced effect on delayed gastric emptying. Dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter 2 inhibitors also reduce postprandial hyperglycemia. To achieve more physiologically normal glycemic control, choice of therapy should ideally aim to address daily glucose fluctuations, including hyperglycemic peaks and hypoglycemic troughs, and long-term glycemic control.

01 Oct 2016·Diabetes, Obesity and MetabolismQ2 · MEDICINE

Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon‐like peptide‐1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD‐4 substudy

Q2 · MEDICINE

Article

Author: Milicevic, Zvonko ; Jiang, Honghua ; Jendle, Johan ; Testa, Marcia A. ; Martin, Sherry

AimTo conduct a substudy, using 24‐hour continuous glucose monitoring (CGM), of the AWARD‐4 trial, which was designed to compare insulin + glucagon‐like peptide‐1 receptor agonist treatment with an insulin‐only regimen.MethodsThe AWARD‐4 trial randomized 884 conventional insulin regimen‐treated patients to dulaglutide 1.5 mg, dulaglutide 0.75 mg and glargine, all in combination with prandial insulin lispro. The CGM substudy included 144 patients inserted with a Medtronic CGMS iPro CGM device to enable 3‐day glucose monitoring. CGM sessions were completed at weeks 0, 13, 26 and 52. CGM measures included mean 24‐hour glucose, percentage time in target glucose ranges, hyper‐ and hypoglycaemia and glucose variability. The primary objective was treatment comparison for percentage time spent with CGM glucose values in the 3.9‐7.8 mmol/L range after 26 weeks.ResultsAt week 26, mean CGM values decreased in all treatment groups (change from baseline −2.8 ± 0.3, −2.4 ± 0.3 and −2.5 ± 0.3 mmol/L for dulaglutide 1.5 mg, dulaglutide 0.75 mg and glargine, respectively); between‐group differences were not statistically significant. Treatment groups were similar for percentage time in the 3.9‐7.8 mmol/L range. Percentage time in the 3.9‐10.0 mmol/L range was greater for dulaglutide 1.5 mg than for glargine (p < 0.05). Dulaglutide and glargine were associated with decreased glucose variability for all CGM variability indices. The overall within‐patient standard deviation (s.d.) was significantly reduced with dulaglutide 1.5 mg versus glargine (p < 0.05). At week 52, there were no significant differences among the groups with regard to measures of normoglycaemia or near‐normoglycaemia and for the overall within‐patient s.d. Treatment with glargine was associated with greater increases in percentage time spent with glucose values ≤3.9 mmol/L, with statistically significant differences between the groups at 52 weeks (p < 0.05).ConclusionsIn combination with prandial lispro, treatment with dulaglutide and glargine resulted in similar proportions of glucose values in the normoglycaemic range, but dulaglutide provided an improved balance between the proportion of values within the near‐normoglycaemia range and values within the hypoglycaemic range.

01 Feb 2013·Diabetes Technology & TherapeuticsQ2 · MEDICINE

New Insulins and Insulin Therapy

Q2 · MEDICINE

Review

Author: Danne, Thomas ; Bolinder, Jan

While the pharmacokinetic properties of the long-acting insulin analogues, insulin glargine and insulin detemir, clearly demonstrate clinical benefits over NPH insulin in terms of reduced frequency of overall and nocturnal hypoglycaemic events and lowered glycaemic variability, several new insulin analogues with even longer and smoother time-action profiles are being developed and explored. Among these, insulin degludec is the first to enter the market. The ultra-long action profile of this insulin analogue is mainly the result of a slow and stable release of insulin degludec monomers from soluble multihexamers that form after subcutaneous administration. In the last year, the results of the first phase II trials with insulin degludec have been published, where the efficacy and safety of this basal insulin analogue have been compared with insulin glargine in patients with type 1 (T1D) and type 2 (T2D) diabetes. With regard to short-acting insulins for mealtime insulin supplementation, there is also a search for new insulins with a more rapid onset of action, and hence improved postprandial glucose control. Linjeta (formerly named VIAject) is a human insulin formulation with faster insulin absorption and action than insulin lispro and regular human insulin. A new drug application to market Linjeta as a treatment for diabetes was submitted to the US Food and Drug Administration (FDA) by the manufacturer at the beginning of 2010. However, the FDA’s review cycle, which was announced late in 2010, concluded that the application could not be approved in its present form. The FDA’s complete response letter included comments related to clinical trials, statistical analysis and chemistry, manufacturing and controls. The FDA requested that the company should conduct two new phase III clinical trials using the commercial formulation, one in patients with T1D and the other in patients with T2D, to establish efficacy and safety with regard to hypoglycaemia and toleration. Co-administration of hyaluronidase together with insulin is another novel concept which has been proven to accelerate the absorption of both insulin lispro and regular human insulin in healthy subjects. In this review, we comment on two recent publications in which the pharmacokinetic and pharmacodynamic characteristics of Linjeta and co-formulations of prandial insulins with recombinant human hyaluronidase were investigated in patients with T1D. Lastly, a recent review on the ongoing discussion regarding insulin treatment and cancer risk is included.

100 Deals associated with Insulin prandial injectable(Albireo Pharma, Inc.)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hyperglycemia	NDA/BLA	US	Biodel, Inc.	01 Apr 2010
Diabetes Mellitus, Type 1	NDA/BLA	-	Albireo Pharma, Inc.	-
Diabetes Mellitus, Type 1	NDA/BLA	-	Albireo Pharma, Inc.	-
Diabetes Mellitus, Type 2	NDA/BLA	-	Albireo Pharma, Inc.	-
Diabetes Mellitus, Type 2	NDA/BLA	-	Albireo Pharma, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis